0000950170-24-017091.txt : 20240220 0000950170-24-017091.hdr.sgml : 20240220 20240220160546 ACCESSION NUMBER: 0000950170-24-017091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelly Thomas Patrick CENTRAL INDEX KEY: 0001410514 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 24653233 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, INC. STREET 2: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 ownership.xml 4 X0508 4 2024-02-15 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001410514 Kelly Thomas Patrick C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 false true false false Chief Financial Officer false Common Stock 2024-02-15 4 A false 17275 0 A 83360 D Common Stock 2024-02-16 4 S false 3010 15.6177 D 80350 D Stock Option (Right to Buy) 15.92 2024-02-15 4 A false 69100 0 A 2034-02-14 Common Stock 69100 69100 D The reporting person was awarded 17,275 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2025, February 15, 2026 and February 15, 2027. This sale was to cover tax liabilities in the vesting of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6175 to $15.6177, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024. /s/ Jeffrey M. Held, Attorney-in-Fact 2024-02-20